1. |
Cho SY, Lee TH, Ku YH, et al. Central lymph node metastasis in papillary thyroid microcarcinoma can be stratified according to the number, the size of metastatic foci, and the presence of desmoplasia. Surgery, 2015, 157(1): 111-118.
|
2. |
Witt RL. What is the best treatment of incidental papillary thyroid microcarcinoma? Laryngoscope, 2016, 126(10): 2203-2204.
|
3. |
Zhou J, Yin L, Wei X, et al. 2020 Chinese guidelines for ultrasound malignancy risk stratification of thyroid nodules: the C-TIRADS. Endocrine, 2020, 70(2): 256-279.
|
4. |
Shaha AR, Tuttle RM. Thyroid cancer staging and genomics. Ann Transl Med, 2019, 7(Suppl1): S49.
|
5. |
Ullmann TM, Gray KD, Moore MD, et al. Current controversies and future directions in the diagnosis and management of differentiated thyroid cancers. Gland Surg, 2018, 7(5): 473-486.
|
6. |
Miranda-Filho A, Lortet-Tieulent J, Bray F, et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol, 2021, 9(4): 225-234.
|
7. |
Davies L, Hoang JK. Thyroid cancer in the USA: current trends and outstanding questions. Lancet Diabetes Endocrinol, 2021, 9(1): 11-12.
|
8. |
Lin JD. Increased incidence of papillary thyroid microcarcinoma with decreased tumor size of thyroid cancer. Med Oncol, 2010, 27(2): 510-518.
|
9. |
Zalzali M, Debreuve A, Richard C, et al. Micropapillary carcinoma: Description and rise in incidence in the French Marne-Ardennes thyroid cancer registry. Ann Endocrinol (Paris), 2019, 80(4): 229-233.
|
10. |
王龙龙, 李红强, 苌群刚, 等. 甲状腺癌21 980例患者临床病理特征与发病趋势分析. 中华医学杂志, 2020, 100(14): 1072-1076.
|
11. |
Hughes DT, Haymart MR, Miller BS, et al. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid, 2011, 21(3): 231-236.
|
12. |
Yu X, Song X, Sun W, et al. Independent risk factors predicting central lymph node metastasis in papillary thyroid microcarcinoma. Horm Metab Res, 2017, 49(3): 201-207.
|
13. |
Samà MT, Grosso E, Mele C, et al. Molecular characterisation and clinical correlation of papillary thyroid microcarcinoma. Endocrine, 2021, 71(1): 149-157.
|
14. |
Al-Qurayshi Z, Nilubol N, Tufano RP, et al. Wolf in sheep’s clothing: papillary thyroid microcarcinoma in the US. J Am Coll Surg, 2020, 230(4): 484-491.
|
15. |
Zhang Q, Wang Z, Meng X, et al. Predictors for central lymph node metastases in cN0 papillary thyroid microcarcinoma (mPTC): A retrospective analysis of 1 304 cases. Asian J Surg, 2019, 42(4): 571-576.
|
16. |
Liu LS, Liang J, Li JH, et al. The incidence and risk factors for central lymph node metastasis in cN0 papillary thyroid microcarcinoma: a meta-analysis. Eur Arch Otorhinolaryngol, 2017, 274(3): 1327-1338.
|
17. |
Lee J, Song Y, Soh EY. Central lymph node metastasis is an important prognostic factor in patients with papillary thyroid microcarcinoma. J Korean Med Sci, 2014, 29(1): 48-52.
|
18. |
Hwangbo Y, Kim JM, Park YJ, et al. Long-term recurrence of small papillary thyroid cancer and its risk factors in a Korean multicenter study. J Clin Endocrinol Metab, 2017, 102(2): 625-633.
|
19. |
Wang W, Su X, He K, et al. Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: An updated study with more than 2000 consecutive patients. Cancer, 2016, 122(2): 198-206.
|
20. |
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2016, 26(1): 1-133.
|
21. |
Ryu YJ, Yoon JH. Impact of prophylactic unilateral central neck dissection needed for patients with papillary thyroid microcarcinoma. Gland Surg, 2020, 9(2): 352-361.
|
22. |
Dobrinja C, Troian M, Cipolat Mis T, et al. Rationality in prophylactic central neck dissection in clinically node-negative (cN0) papillary thyroid carcinoma: Is there anything more to say? A decade experience in a single-center. Int J Surg, 2017, 41Suppl1: S40-S47.
|
23. |
高明, 葛明华, 嵇庆海, 等. 甲状腺微小乳头状癌诊断与治疗中国专家共识(2016版). 中国肿瘤临床, 2016, 43(10): 405-411.
|
24. |
董文武, 张浩. 2018年版日本《甲状腺肿瘤诊疗指南》外科治疗部分更新解读. 中国实用外科杂志, 2019, 39(12): 1260-1264.
|
25. |
Wang JB, Sun YY, Shi LH, et al. Predictive factors for non-small-volume central lymph node metastases (more than 5 or ≥2 mm) in clinically node-negative papillary thyroid carcinoma. Medicine (Baltimore), 2019, 98(1): e14028. doi: 10.1097/MD.0000000000014028.
|
26. |
Liu C, Liu Y, Zhang L, et al. Risk factors for high-volume lymph node metastases in cN0 papillary thyroid microcarcinoma. Gland Surg, 2019, 8(5): 550-556.
|
27. |
Song J, Yan T, Qiu W, et al. Clinical analysis of risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: A retrospective study of 3 686 patients. Cancer Manag Res, 2020, 12: 2523-2530.
|
28. |
Xu Y, Xu L, Wang J. Clinical predictors of lymph node metastasis and survival rate in papillary thyroid microcarcinoma: analysis of 3 607 patients at a single institution. J Surg Res, 2018, 221: 128-134.
|
29. |
Yan T, Qiu W, Song J, et al. Bilateral multifocality, a marker for aggressive disease, is not an independent prognostic factor for papillary thyroid microcarcinoma: A propensity score matching analysis. Clin Endocrinol (Oxf), 2021, 95(1): 209-216.
|
30. |
Pyo JS, Sohn JH, Kang G. Detection of tumor multifocality is important for prediction of tumor recurrence in papillary thyroid microcarcinoma: A retrospective study and meta-analysis. J Pathol Transl Med, 2016, 50(4): 278-286.
|
31. |
Wu X, Li BL, Zheng CJ, et al. Predictive factors for central lymph node metastases in papillary thyroid microcarcinoma. World J Clin Cases, 2020, 8(8): 1350-1360.
|
32. |
Tam AA, Özdemir D, Çuhacı N, et al. Association of multifocality, tumor number, and total tumor diameter with clinicopathological features in papillary thyroid cancer. Endocrine, 2016, 53(3): 774-783.
|
33. |
Feng JW, Pan H, Wang L, et al. Total tumor diameter: the neglected value in papillary thyroid microcarcinoma. J Endocrinol Invest, 2020, 43(5): 601-613.
|
34. |
Pyo JS, Sohn JH, Kang G, et al. Total surface area is useful for differentiating between aggressive and favorable multifocal papillary thyroid carcinomas. Yonsei Med J, 2015, 56(2): 355-361.
|
35. |
Tam AA, Özdemir D, Çuhacı N, et al. Can ratio of the biggest tumor diameter to total tumor diameter be a new parameter in the differential diagnosis of agressive and favorable multifocal papillary thyroid microcarcinoma? Oral Oncol, 2017, 65: 1-7.
|
36. |
Zhu M, Zheng W, Xiang Y, et al. The relationship between central lymph node metastasis and the distance from tumor to thyroid capsule in papillary thyroid microcarcinoma without capsule invasion. Gland Surg, 2020, 9(3): 727-736.
|
37. |
Kim KJ, Kim SM, Lee YS, et al. Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor size: a retrospective study of 2 309 consecutive patients. Ann Surg Oncol, 2015, 22(1): 125-131.
|
38. |
Wang F, Yu X, Shen X, et al. The prognostic value of tumor multifocality in clinical outcomes of papillary thyroid cancer. J Clin Endocrinol Metab, 2017, 102(9): 3241-3250.
|
39. |
Shattuck TM, Westra WH, Ladenson PW, et al. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med, 2005, 352(23): 2406-2412.
|
40. |
Jovanovic L, Delahunt B, McIver B, et al. Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone. J Pathol, 2008, 215(2): 145-154.
|
41. |
Bansal M, Gandhi M, Ferris RL, et al. Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma. Am J Surg Pathol, 2013, 37(10): 1586-1591.
|
42. |
严丽, 李清怀, 冀宏, 等. 多灶甲状腺微小乳头状癌的临床特征分析. 中国普通外科杂志, 2016, 25(11): 1568-1572.
|
43. |
何杰, 李新营, 王志明, 等. 多灶性甲状腺微小乳头状癌临床病理特征及预防性中央区淋巴结清扫的意义. 中国普通外科杂志, 2017, 26(11): 1405-1410.
|
44. |
殷德涛, 韩飏, 张亚原, 等. 多灶性甲状腺乳头状癌的临床病理及颈淋巴结转移特征. 中国普通外科杂志, 2017, 26(5): 556-560.
|
45. |
Wu X, Li B, Zheng C, et al. Risk factors for central lymph node metastases in patients with papillary thyroid microcarcinoma. Endocr Pract, 2018, 24(12): 1057-1062.
|
46. |
Gong Y, Li G, Lei J, et al. A favorable tumor size to define papillary thyroid microcarcinoma: an analysis of 1176 consecutive cases. Cancer Manag Res, 2018, 10: 899-906.
|
47. |
Huang Y, Yin Y, Zhou W. Risk factors for central and lateral lymph node metastases in patients with papillary thyroid micro-carcinoma: Retrospective analysis on 484 cases. Front Endocrinol (Lausanne), 2021, 12: 640565. doi: 10.3389/fendo.2021.640565.
|
48. |
Cai J, Fang F, Chen J, et al. Unilateral Multifocality and bilaterality could be two different multifocal entities in patients with papillary thyroid microcarcinoma. Biomed Res Int, 2020, 2020: 9854964. doi: 10.1155/2020/9854964.
|
49. |
Lee KJ, Cho YJ, Kim SJ, et al. Analysis of the clinicopathologic features of papillary thyroid microcarcinoma based on 7-mm tumor size. World J Surg, 2011, 35(2): 318-323.
|
50. |
Zheng X, Peng C, Gao M, et al. Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a study of 1 587 patients. Cancer Biol Med, 2019, 16(1): 121-130.
|
51. |
Liu C, Wang S, Zeng W, et al. Total tumour diameter is superior to unifocal diameter as a predictor of papillary thyroid microcarcinoma prognosis. Sci Rep, 2017, 7(1): 1846. doi: 10.1038/s41598-017-02165-6.
|
52. |
Zhao Q, Ming J, Liu C, et al. Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma. Ann Surg Oncol, 2013, 20(3): 746-752.
|
53. |
Zhou B, Wei L, Qin J. Does Multifocal papillary thyroid microcarcinoma with a total tumor diameter >1 cm indicate poor biological behavior? The evidence is insufficient. Endocr Pract, 2021, 27(2): 131-136.
|
54. |
Andea AA, Bouwman D, Wallis T, et al. Correlation of tumor volume and surface area with lymph node status in patients with multifocal/multicentric breast carcinoma. Cancer, 2004, 100(1): 20-27.
|
55. |
Tuttle RM, Fagin JA, Minkowitz G, et al. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol Head Neck Surg, 2017, 143(10): 1015-1020.
|
56. |
Chung SR, Choi YJ, Lee SS, et al. Interobserver reproducibility in sonographic measurement of diameter and volume of papillary thyroid microcarcinoma. Thyroid, 2021, 31(3): 452-458.
|
57. |
Kaliszewski K, Diakowska D, Wojtczak B, et al. Which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”? World J Surg Oncol, 2019, 17(1): 91. doi: 10.1186/s12957-019-1638-0.
|
58. |
魏涛, 李志辉, 朱精强. 喉返神经探测仪实时监测在再次甲状腺手术中的应用. 中国普外基础与临床杂志, 2010, 17(8): 772-774.
|
59. |
Revelli L, Damiani G, Bianchi CB, et al. scalpel, Harmonic focus versus conventional hemostasis: A meta-analysis. Int J Surg, 2016, 28 Suppl1: S22-S32.
|